510(k) device
XEN Glaucoma Treatment System
Allergan, Inc. · Implant, Eye Valve (KYF, Class II) · First FDA decision Nov 21, 2016, newest Nov 21, 2016Glaucoma
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
9
Naming "XEN Glaucoma Treatment"
MAUDE reports
0
Brand "XEN Glaucoma Treatment", since 2015
PubMed studies
6
Mentioning "XEN Glaucoma Treatment"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing XEN Glaucoma Treatment System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 1 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "XEN Glaucoma Treatment", any status and sponsor, newest update first.
- Comparing XEN®-63 Gel Stent and PRESERFLO® MicroShuntPivotal-lookingRecruiting
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
NCT07359547 · 166 participants (planned) · Start Jan 1, 2026 · Primary completion Jan 2027
Device: XEN®-63 Gel Stent; PRESERFLO™ MicroShunt · For: GLAUCOMA 1, OPEN ANGLE, D (Disorder)
Sites: Leuven, Belgium; Bonn, Germany; Lisbon, Portugal
- XEN Glaucoma Gel Stent Versus TrabeculectomyPivotal-lookingRecruiting
Prof. Dr. Herbert ReitsamerAcademic, hospital or other
NCT05439161 · 196 participants (planned) · Start Dec 20, 2023 · Primary completion Mar 31, 2026
Device: surgery · For: Primary Open Angle Glaucoma; Pseudoexfoliation Glaucoma; Pigmentary Dispersion Glaucoma
Sites: Salzburg, Austria
AllerganNot on our public-company list
NCT04303897 · 59 participants · Start Dec 19, 2019 · Primary completion Mar 3, 2022
Device: XEN Glaucoma Stent · For: Refractory Glaucoma
Sites: Qionghai, China
6 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "XEN Glaucoma Treatment", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code KYF
3,772 reports: 1,109 malfunction, 2,659 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "XEN Glaucoma Treatment"[tiab]. The summary above synthesizes these.
- Italian XEN-Glaucoma Treatment Registry (XEN-GTR): Effectiveness and Safety at 36 Months of XEN45 Implant.
Oddone F, Roberti G, Giammaria S, et al. · J Clin Med · 2024
- XEN glaucoma treatment system in the management of refractory glaucomas: a short review on trial data and potential role in clinical practice.
De Gregorio A, Pedrotti E, Stevan G, et al. · Clin Ophthalmol · 2018Review
- Italian Candidates for the XEN Implant: An Overview from the Glaucoma Treatment Registry (XEN-GTR).
Posarelli C, Figus M, Roberti G, et al. · J Clin Med · 2022
- Effectiveness and safety of XEN45 implant over 12 months of follow-up: data from the XEN-Glaucoma Treatment Registry.
Oddone F, Roberti G, Giammaria S, et al. · Eye (Lond) · 2024Observational Study, Multicenter Study
- Endothelial Cell Density After XEN Implant Surgery: Short-term Data From the Italian XEN Glaucoma Treatment Registry (XEN-GTR).
Oddone F, Roberti G, Posarelli C, et al. · J Glaucoma · 2021Multicenter Study, Observational Study
- Safety and Effectiveness of a Gel Stent in Refractory Glaucoma in China: Real-World Evidence at 12 Months.
Liang Y, Zhu Y, Wang N, et al. · Clin Ophthalmol · 2026
Other devices of this type
Also filed under product code KYF.
- Ahmed® Glaucoma Valve Model FP8New World Medical, Inc. · 510(k) 2023
- iStent infinite Trabecular Micro-Bypass System, Model iS3Glaukos Corporation · 510(k) 2022
- AHMED ClearPath Glaucoma Drainage DeviceNew World Medical, Inc. · 510(k) 2019
- Molteno3 Glaucoma ImplantInnovative Ophthalmic Products, Inc. (Iop) · 510(k) 2015
- MOLTENO3Iop, Inc. · 510(k) 2006
- Express Mini Glaucoma ShuntOptonol, Ltd. · 510(k) 2003
- Ex-Press Minature Glaucoma Implant, Models R-20, R-30, R-50, Sts VersionsOptonol, Ltd. · 510(k) 2002
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.